- 移动端
MedChemExpress LLC品牌商
14 年
手机商铺
商家活跃：
产品热度：
- NaN
- 0
- 0
- 2
- 2
推荐产品
公司新闻/正文
EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses
308 人阅读发布时间：2020-11-18 15:16
EIDD-2801 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。EIDD-2801 显示出广泛的抗流感病毒 (influenza virus) 和冠状病毒 (coronaviruses) 的活性，如 SARS-CoV-2，MERS-CoV，SARS-CoV。EIDD-2801 有用于 COVID-19 和季节性，流行性流感的潜力。
产品描述：
EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment。
体内实验：
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution
2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution
3. 请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution
产品描述：
EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment。
体内实验：
EIDD-2801 (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1].
EIDD-2801 (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 mice (intranasal infection with SARS-CoV)[1] |
| Dosage: | 50, 150, 500 mg/kg |
| Administration: | Oral; every 12 hours for 3 days |
| Result: | Body weight loss is significantly diminished or prevented. |
| Animal Model: | Ca/09-infected female ferrets[1] |
| Dosage: | 7 mg/kg |
| Administration: | Oral; twice daily for 3.5 days |
| Result: | Shed virus load and duration of fever were significantly reduced. |
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution
2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution
3. 请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution